The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global NAD+ Intravenous Market Research Report 2024
Synopsis
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in all living cells and plays a crucial role in various biological processes, including energy metabolism and DNA repair. Intravenous (IV) administration of NAD+ involves delivering this coenzyme directly into the
The global NAD+ Intravenous market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for NAD+ Intravenous is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for NAD+ Intravenous is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for NAD+ Intravenous in Clinic is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of NAD+ Intravenous include Invigor Medical, Empower Pharmacy, Azivmedics, Reset IV, Gtrsante, Mobileivmedics, Conciergemdla, The Wellness Lab and Rocky Mountain Ivmedics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for NAD+ Intravenous, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding NAD+ Intravenous.
Report Scope
The NAD+ Intravenous market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global NAD+ Intravenous market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the NAD+ Intravenous companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Invigor Medical
Empower Pharmacy
Azivmedics
Reset IV
Gtrsante
Mobileivmedics
Conciergemdla
The Wellness Lab
Rocky Mountain Ivmedics
Seaside Skin Care
Revivme
Premiumhealth
Effect Doctors
Nadclinic
Thedripclub
Next-health
Segment by Type
Hybrid Type
Pure NAD+ Type
Segment by Application
Clinic
Hospital
Residential
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of NAD+ Intravenous companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in all living cells and plays a crucial role in various biological processes, including energy metabolism and DNA repair. Intravenous (IV) administration of NAD+ involves delivering this coenzyme directly into the
The global NAD+ Intravenous market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for NAD+ Intravenous is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for NAD+ Intravenous is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for NAD+ Intravenous in Clinic is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of NAD+ Intravenous include Invigor Medical, Empower Pharmacy, Azivmedics, Reset IV, Gtrsante, Mobileivmedics, Conciergemdla, The Wellness Lab and Rocky Mountain Ivmedics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for NAD+ Intravenous, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding NAD+ Intravenous.
Report Scope
The NAD+ Intravenous market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global NAD+ Intravenous market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the NAD+ Intravenous companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Invigor Medical
Empower Pharmacy
Azivmedics
Reset IV
Gtrsante
Mobileivmedics
Conciergemdla
The Wellness Lab
Rocky Mountain Ivmedics
Seaside Skin Care
Revivme
Premiumhealth
Effect Doctors
Nadclinic
Thedripclub
Next-health
Segment by Type
Hybrid Type
Pure NAD+ Type
Segment by Application
Clinic
Hospital
Residential
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of NAD+ Intravenous companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global NAD+ Intravenous Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Hybrid Type
1.2.3 Pure NAD+ Type
1.3 Market by Application
1.3.1 Global NAD+ Intravenous Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Residential
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global NAD+ Intravenous Market Perspective (2019-2030)
2.2 NAD+ Intravenous Growth Trends by Region
2.2.1 Global NAD+ Intravenous Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 NAD+ Intravenous Historic Market Size by Region (2019-2024)
2.2.3 NAD+ Intravenous Forecasted Market Size by Region (2025-2030)
2.3 NAD+ Intravenous Market Dynamics
2.3.1 NAD+ Intravenous Industry Trends
2.3.2 NAD+ Intravenous Market Drivers
2.3.3 NAD+ Intravenous Market Challenges
2.3.4 NAD+ Intravenous Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top NAD+ Intravenous Players by Revenue
3.1.1 Global Top NAD+ Intravenous Players by Revenue (2019-2024)
3.1.2 Global NAD+ Intravenous Revenue Market Share by Players (2019-2024)
3.2 Global NAD+ Intravenous Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by NAD+ Intravenous Revenue
3.4 Global NAD+ Intravenous Market Concentration Ratio
3.4.1 Global NAD+ Intravenous Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by NAD+ Intravenous Revenue in 2023
3.5 NAD+ Intravenous Key Players Head office and Area Served
3.6 Key Players NAD+ Intravenous Product Solution and Service
3.7 Date of Enter into NAD+ Intravenous Market
3.8 Mergers & Acquisitions, Expansion Plans
4 NAD+ Intravenous Breakdown Data by Type
4.1 Global NAD+ Intravenous Historic Market Size by Type (2019-2024)
4.2 Global NAD+ Intravenous Forecasted Market Size by Type (2025-2030)
5 NAD+ Intravenous Breakdown Data by Application
5.1 Global NAD+ Intravenous Historic Market Size by Application (2019-2024)
5.2 Global NAD+ Intravenous Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America NAD+ Intravenous Market Size (2019-2030)
6.2 North America NAD+ Intravenous Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America NAD+ Intravenous Market Size by Country (2019-2024)
6.4 North America NAD+ Intravenous Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe NAD+ Intravenous Market Size (2019-2030)
7.2 Europe NAD+ Intravenous Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe NAD+ Intravenous Market Size by Country (2019-2024)
7.4 Europe NAD+ Intravenous Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific NAD+ Intravenous Market Size (2019-2030)
8.2 Asia-Pacific NAD+ Intravenous Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific NAD+ Intravenous Market Size by Region (2019-2024)
8.4 Asia-Pacific NAD+ Intravenous Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America NAD+ Intravenous Market Size (2019-2030)
9.2 Latin America NAD+ Intravenous Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America NAD+ Intravenous Market Size by Country (2019-2024)
9.4 Latin America NAD+ Intravenous Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa NAD+ Intravenous Market Size (2019-2030)
10.2 Middle East & Africa NAD+ Intravenous Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa NAD+ Intravenous Market Size by Country (2019-2024)
10.4 Middle East & Africa NAD+ Intravenous Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Invigor Medical
11.1.1 Invigor Medical Company Detail
11.1.2 Invigor Medical Business Overview
11.1.3 Invigor Medical NAD+ Intravenous Introduction
11.1.4 Invigor Medical Revenue in NAD+ Intravenous Business (2019-2024)
11.1.5 Invigor Medical Recent Development
11.2 Empower Pharmacy
11.2.1 Empower Pharmacy Company Detail
11.2.2 Empower Pharmacy Business Overview
11.2.3 Empower Pharmacy NAD+ Intravenous Introduction
11.2.4 Empower Pharmacy Revenue in NAD+ Intravenous Business (2019-2024)
11.2.5 Empower Pharmacy Recent Development
11.3 Azivmedics
11.3.1 Azivmedics Company Detail
11.3.2 Azivmedics Business Overview
11.3.3 Azivmedics NAD+ Intravenous Introduction
11.3.4 Azivmedics Revenue in NAD+ Intravenous Business (2019-2024)
11.3.5 Azivmedics Recent Development
11.4 Reset IV
11.4.1 Reset IV Company Detail
11.4.2 Reset IV Business Overview
11.4.3 Reset IV NAD+ Intravenous Introduction
11.4.4 Reset IV Revenue in NAD+ Intravenous Business (2019-2024)
11.4.5 Reset IV Recent Development
11.5 Gtrsante
11.5.1 Gtrsante Company Detail
11.5.2 Gtrsante Business Overview
11.5.3 Gtrsante NAD+ Intravenous Introduction
11.5.4 Gtrsante Revenue in NAD+ Intravenous Business (2019-2024)
11.5.5 Gtrsante Recent Development
11.6 Mobileivmedics
11.6.1 Mobileivmedics Company Detail
11.6.2 Mobileivmedics Business Overview
11.6.3 Mobileivmedics NAD+ Intravenous Introduction
11.6.4 Mobileivmedics Revenue in NAD+ Intravenous Business (2019-2024)
11.6.5 Mobileivmedics Recent Development
11.7 Conciergemdla
11.7.1 Conciergemdla Company Detail
11.7.2 Conciergemdla Business Overview
11.7.3 Conciergemdla NAD+ Intravenous Introduction
11.7.4 Conciergemdla Revenue in NAD+ Intravenous Business (2019-2024)
11.7.5 Conciergemdla Recent Development
11.8 The Wellness Lab
11.8.1 The Wellness Lab Company Detail
11.8.2 The Wellness Lab Business Overview
11.8.3 The Wellness Lab NAD+ Intravenous Introduction
11.8.4 The Wellness Lab Revenue in NAD+ Intravenous Business (2019-2024)
11.8.5 The Wellness Lab Recent Development
11.9 Rocky Mountain Ivmedics
11.9.1 Rocky Mountain Ivmedics Company Detail
11.9.2 Rocky Mountain Ivmedics Business Overview
11.9.3 Rocky Mountain Ivmedics NAD+ Intravenous Introduction
11.9.4 Rocky Mountain Ivmedics Revenue in NAD+ Intravenous Business (2019-2024)
11.9.5 Rocky Mountain Ivmedics Recent Development
11.10 Seaside Skin Care
11.10.1 Seaside Skin Care Company Detail
11.10.2 Seaside Skin Care Business Overview
11.10.3 Seaside Skin Care NAD+ Intravenous Introduction
11.10.4 Seaside Skin Care Revenue in NAD+ Intravenous Business (2019-2024)
11.10.5 Seaside Skin Care Recent Development
11.11 Revivme
11.11.1 Revivme Company Detail
11.11.2 Revivme Business Overview
11.11.3 Revivme NAD+ Intravenous Introduction
11.11.4 Revivme Revenue in NAD+ Intravenous Business (2019-2024)
11.11.5 Revivme Recent Development
11.12 Premiumhealth
11.12.1 Premiumhealth Company Detail
11.12.2 Premiumhealth Business Overview
11.12.3 Premiumhealth NAD+ Intravenous Introduction
11.12.4 Premiumhealth Revenue in NAD+ Intravenous Business (2019-2024)
11.12.5 Premiumhealth Recent Development
11.13 Effect Doctors
11.13.1 Effect Doctors Company Detail
11.13.2 Effect Doctors Business Overview
11.13.3 Effect Doctors NAD+ Intravenous Introduction
11.13.4 Effect Doctors Revenue in NAD+ Intravenous Business (2019-2024)
11.13.5 Effect Doctors Recent Development
11.14 Nadclinic
11.14.1 Nadclinic Company Detail
11.14.2 Nadclinic Business Overview
11.14.3 Nadclinic NAD+ Intravenous Introduction
11.14.4 Nadclinic Revenue in NAD+ Intravenous Business (2019-2024)
11.14.5 Nadclinic Recent Development
11.15 Thedripclub
11.15.1 Thedripclub Company Detail
11.15.2 Thedripclub Business Overview
11.15.3 Thedripclub NAD+ Intravenous Introduction
11.15.4 Thedripclub Revenue in NAD+ Intravenous Business (2019-2024)
11.15.5 Thedripclub Recent Development
11.16 Next-health
11.16.1 Next-health Company Detail
11.16.2 Next-health Business Overview
11.16.3 Next-health NAD+ Intravenous Introduction
11.16.4 Next-health Revenue in NAD+ Intravenous Business (2019-2024)
11.16.5 Next-health Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
